A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Clinical trial NCT01296555 · TERMINATED
Trial details
- NCT number
- NCT01296555
- Sponsor
- Genentech, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-03-16
- Primary completion
- 2021-06-25
- Enrollment
- 674
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.